Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Overweight rating and $11 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Eupraxia Pharmaceuticals to Present at Key Investor Conferences
- Promising Developments in Eupraxia Pharmaceuticals’ EoE Trial Justify Buy Rating
- Eupraxia Pharmaceuticals Advances RESOLVE Trial with First Patient Dosed in Phase 2b
- Eupraxia Pharma doses first patient in Phase 2b trial of EP-104GI in esophagitis
- Promising Future for Eupraxia Pharmaceuticals: Buy Rating Affirmed on Strong EP-104GI Trial Results